Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores
Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores
复制标题
DOI：
10.1128/aac.01611-12
复制
发表时间：
2013-01-01
影响因子：
4.9
通讯作者：
Sorg, Joseph A.
中科院分区：
文献类型：
--
作者：
Allen, Charlotte A.;Babakhani, Farah;Sorg, Joseph A.
Fidaxomicin (FDX) is approved to treat Clostridium difficile-associated diarrhea and is superior to vancomycin in providing a sustained clinical response (cure without recurrence in the subsequent 25 days). The mechanism(s) behind the low recurrence rate of FDX-treated patients could be multifactorial. Here, we tested effects of FDX, its metabolite OP-1118, and vancomycin on spore germination and determined that none affected the initiation of spore germination but all inhibited outgrowth of vegetative cells from germinated spores.
